ANITA SCHIERLINGER: Open Payments
NPI 1720220312 · NORTH BRANCH, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 34 payments from 13 companies in 2025. Trend: 2023 $517 · 2024 $598 · 2025 $636
Food & beverage: $636
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $164 |
| ABBVIE INC. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Exact Sciences Corporation | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Lilly USA, LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: Wegovy, REXULTI, Qelbree, VRAYLAR, TRELEGY ELLIPTA, Auvelity, MOUNJARO, CAPLYTA.
Industry payments across MI — which companies pay providers there.
